Test Price
1,000 AED✅ Home Collection Available
AML ETO t(8;21) Gene Rearrangement Quantitative MRD Monitor Test
Executive Summary & Core Metrics
Executive Summary
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing.
- Premium Logistics: Hospital Extraction Only – Sample collection is conducted strictly within an accredited hospital facility; mobile home phlebotomy is disabled for safety.
- Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation.
- Insurance: Direct Billing Verification via WhatsApp +971545488731.
Test Overview & Methodology
The AML ETO t(8;21) Gene Rearrangement Quantitative MRD Monitor Test uses highly sensitive Real-Time PCR to quantify the AML1-ETO (RUNX1-RUNX1T1) fusion transcript in blood or bone marrow. This minimally invasive assay allows dynamic tracking of minimal residual disease (MRD) for patients with core-binding factor AML, aiding precise treatment de-escalation and early relapse detection. Our method outperforms conventional cytogenetics, delivering actionable results within 3 working days.
| Parameter | Our Test (AML ETO MRD qPCR) | Closest Alternative (FISH/Karyotyping) |
|---|---|---|
| Analytical Sensitivity | Up to 10⁻⁴ – 10⁻⁵ (1 leukemic cell in 10,000–100,000 normal cells) | 1–5% blast threshold |
| Methodology | Real-Time Quantitative PCR (TaqMan probes, gene-specific primers) | Fluorescence in‑situ hybridization (low resolution) |
| Turnaround Time | 3 working days | 7–10 working days |
| Clinical Utility | Longitudinal MRD kinetics, relapse prediction | Diagnostic / remission status only |
Physician Insight & Safety Protocols
“As a Consultant Medical Genetics, I emphasize that the AML ETO MRD qPCR test provides critical molecular surveillance but must always be interpreted alongside bone marrow morphology and full clinical history. A single negative qPCR does not confirm cure; rising transcript levels precede hematologic relapse by weeks. Never adjust therapy based solely on this assay.”
— Lina Osama Zaki Quteineh, DHA Registration ID: 9294403
⚠️ Medication Advisory
Do not discontinue, modify, or skip prescribed chemotherapy, targeted therapy, or any medication without consulting your treating oncologist. Contact your medical team immediately if a dose is missed or new symptoms occur.
🛑 Patient Safety: Exclusion Criteria & ER Red Flags
- Specimen Rejection: Hemolyzed, clotted, frozen, or incorrect tube samples will not be processed.
- Transfusion Interference: Blood transfusion within 2 weeks may artificially lower MRD levels.
- Emergency Indicators: If you experience fever >38.3°C, severe bleeding, sudden bruising, or bone pain, proceed to the nearest emergency department—these may indicate disease progression or complications.
Patient FAQ & Clinical Guidance
1. What is the purpose of the AML ETO MRD test?
A: The AML ETO MRD test quantitatively measures residual leukemia cells after treatment to detect early relapse. By tracking the fusion gene level over time, your oncologist can assess molecular remission depth and adjust therapy before clinical symptoms appear.
2. How often should MRD monitoring be performed?
A: MRD monitoring frequency depends on your treatment protocol, typically every 3 months during consolidation. More frequent testing (monthly) may be advised in high‑risk settings or when transcript levels are rising; your hematologist will individualize the schedule.
3. Can a negative MRD result mean I am cured?
A: A sustained negative MRD over several tests indicates deep molecular remission, but lifelong follow-up is needed. Late relapses can occur, and occasional monitoring even after 5 years ensures any molecular recurrence is caught early.
UAE Regulatory & Data Privacy Adherence
✅ UAE Regulatory & Data Privacy Compliance
This service adheres to Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical testing safety and patient consent are conducted in accordance with Federal Decree-Law No. 4 of 2016 on Medical Liability. Processing is ISO 9001:2015 certified (Cert: INT/EGQ/2509DA/3139). All patient data is handled under advanced encryption protocols.
Clinical & Logistical Metadata
| Test Name | AML ETO t(8;21) Gene Rearrangement Quantitative MRD Monitor Test |
| Price (AED) | 1000 AED |
| Turnaround Time | 3 working days |
| Sample Type / Matrix | Bone marrow (preferred) or 5 mL whole blood (Lavender EDTA). Hospital Extraction Only – Sample collection is conducted strictly within an accredited hospital facility; mobile home phlebotomy is disabled for safety. |
| Methodology Used | Real-Time Quantitative PCR (TaqMan probes, gene-specific primers) |
| ICD-10-CM Code | C92.0 |
| LOINC Code | 35076-3 |
| DHA Facility License & Laboratory Address | License No: 1143, Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians